Overview

Ixazomib + Pomalidomide + Dexamethasone In MM

Status:
Recruiting

Trial end date:
2022-03-20

Target enrollment:

Participant gender:

Summary

This is a Phase I/II study using the combination of twice weekly ixazomib plus pomalidomide and dexamethasone in relapsed and or refractory multiple myeloma (RRMM) patients.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Paul G. Richardson, MD

Collaborator:

Takeda

Treatments:

BB 1101
Dexamethasone
Dexamethasone acetate
Glycine
Ixazomib
Pomalidomide
Thalidomide